Bottom line
KLOW is not one composition. The best-documented definition is GHK-Cu + KPV + BPC-157 + TB-500, but observed sellers also omit TB-500 or use the same name for KPV + LL-37 + thymosin alpha-1 + BPC-157. A clinic "Quad Healing Blend" returns to the first component set at roughly one-tenth the common GHK-Cu loading. No published study tests any of these exact marketed formulations.
No established or recommended human dose. Composition (especially GHK-Cu loading) varies markedly by vendor.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| AminoCore Research (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 50 / 10 / 10 / 10 mg (80 mg total) | Vendor-declared |
| Durham Peptides (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 50 / 10 / 10 / 10 mg | Vendor-declared; unverified |
| BergdorfBio (2026) | GHK-Cu, KPV, BPC-157, TB-500 | 25 / 10 / 10 / 10 mg (55 mg total) | Vendor-declared |
| KLOW70 variant | GHK-Cu, KPV, BPC-157 | 50 / 10 / 10 mg (no TB-500) | Vendor-declared; TB-500 omitted |
| PeakForce Labs, "KLOW" (2026) | KPV, LL-37, thymosin alpha-1, BPC-157 | 80 mg total; split not consistently published | Incompatible four-component definition; vendor-declared |
| Beverly Hills Rejuvenation Center / 99 Purity Peptides, "Quad Healing Blend" (2026) | GHK-Cu, KPV, BPC-157, TB-500 | About 5 / 1 / 1 / 1 mg in observed listings | Market observation; roughly 10-fold lower GHK-Cu loading than the common 50 mg KLOW listing |
At least three incompatible KLOW definitions are therefore documented: the common four-component set, a three-component KLOW70 variant without TB-500, and PeakForce's immune-oriented four-component set. The adjacent "Quad Healing Blend" shows that even the common component set does not identify a stable loading. All amounts are market observations, not guidance.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| GHK-Cu | See component monograph | None for an observed KLOW definition | No published multi-peptide co-formulation stability study identified |
| KPV | See component monograph | None for an observed KLOW definition | No interaction evidence identified |
| BPC-157 | See component monograph | None for an observed KLOW definition | No interaction evidence identified |
| TB-500 | Present in the common definition; see monograph | None for that definition | Identity ambiguity remains material |
| LL-37 | Present only in the PeakForce definition; see monograph | None for that definition | No interaction evidence identified |
| Thymosin alpha-1 | Present only in the PeakForce definition; see monograph | None for that definition | No interaction evidence identified |
Combination-specific studies
No published peer-reviewed study tests any of the exact KLOW definitions documented here. The cited commercial and clinic pages establish naming and formulation claims only; they are not evidence of efficacy or compatibility.
Safety and interaction uncertainties
The same name can refer to different components, so name alone does not identify exposure.
Fixed mixtures complicate attribution of an unexpected effect to one component.
No combination-specific human safety, interaction, pharmacokinetic, or toxicology data were identified.
No published stability data for the observed multi-peptide formulations were identified.
Identity, purity, sterility, and content cannot be inferred from a listing.
Regulatory and product-quality notes
KLOW and Quad Healing Blend are market names, not regulatory or pharmacopoeial standards.
Regulatory status varies by exact component, product, indication, and jurisdiction.
The cited vendor and clinic pages are low-quality market observations; they do not establish approval or suitability for humans.
WADA status varies by component; BPC-157 and TB-500 are prohibited.
Evidence gaps
No combination-specific study of any observed definition
No stability or compatibility data for the mixtures
No independent content comparison across incompatible definitions
No authoritative naming standard
Sources
AminoCore Research. KLOW Blend Analysis. https://aminocoreresearch.com/articles/klow-blend-bpc-157-tb-500-ghk-cu-kpv accessed 2026-08-06.
Durham Peptides. Inside the KLOW Blend. https://www.durhampeptides.ca/post/inside-klow-blend-four-component-breakdown accessed 2026-08-06.
BergdorfBio. KLOW Stack Guide. https://bergdorfbio.com/en/us/guides/klow-stack-leitfaden accessed 2026-08-06.
Your Peptide Brand. KLOW Blend Research Guide. https://yourpeptidebrand.com/klow-blend-research-guide/ accessed 2026-08-06.
PeakForce Labs. KLOW market page. https://peakforcelabs.com/ accessed 2026-08-08.
Beverly Hills Rejuvenation Center. Quad Healing Blend clinic page. https://bhrcenter.com/ accessed 2026-08-08.
99 Purity Peptides. Quad Healing Blend market page. https://99puritypeptides.com/ accessed 2026-08-08.
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf